One stale site document can hold an activation milestone while the same team chases follow-up across the study. Clinical trial workflow automation lets AI agents prepare the startup package, track the dependency, and carry the open action into the next review. Study professionals get a complete trail without giving up clinical or safety judgment.
20+ years building production software · 100+ products shipped across complex environments
Startup Desk
Site 014 · 2 documents outstanding
Activation Watch
6 sites · dependencies by owner
Monitoring Follow-up
Visit complete · action draft ready
TMF Exception Desk
Study file · 11 exceptions sorted
Study Issue Desk
New issue · function proposed
Quality Evidence
Internal review · 3 gaps surfaced
Safety, clinical, protocol, quality, and regulatory judgment stays with the qualified study roles responsible for it.
Across CROs, site networks, and clinical operations teams, multi-site studies move through controlled documents, shared services, and named functional owners.
What makes this work
What stays with your team
One late document or unclear action owner is a site problem. Repeated across a portfolio, it becomes startup delay, monitoring drag, and quality work that compounds.
Startup reviews find one gap at a time
Site documents arrive on different schedules and under different names. Each pass reveals another missing, stale, or unmatched item before activation can advance.
Monitoring follow-up becomes a second visit
Notes, observations, actions, owners, and due dates must be reconstructed after the visit before the site receives a clear follow-up.
TMF exceptions age without a durable owner
A missing or misfiled artifact moves across site, study, and document teams. Everyone sees the exception; nobody sees the full resolution path.
Quality evidence competes with live study work
Teams recreate versions, approvals, and event history when a review begins instead of carrying that trail with the process from the start.
The best first build makes a study team faster at preparing, routing, and closing work it already knows how to review.
Catch the Stale Startup Document Before Review
Study startup automation should make the site package reviewable, not declare it complete. When two documents are stale and one is tied to the wrong requirement, the agent builds the checklist and points to each exception. Startup staff confirm applicability and ownership before accepted status returns to the activation worklist.
Turn the Blocked Milestone Into an Owner
A milestone says blocked without showing whether the cause is a document, approval, system access, or site action. The agent traces the recorded prerequisites and builds a blocker brief by owner. The study team decides the intervention, and the milestone leaves with a due date and responsible function.
Have Monitoring Follow-up Ready for the CRA
The CRA—not the agent—judges significance and wording after a monitoring visit. The agent turns approved notes into a draft list of actions, owners, and dates with links to the supporting material. Once the CRA accepts it, the follow-up is released and the current site worklist updates.
Keep the TMF Exception Attached to Its Artifact
A trial artifact is late, duplicated, or filed against the wrong site. The agent identifies the study, site, artifact, version, and likely owner without changing the controlled record. TMF staff confirm classification and disposition; the worklist keeps the resolution and evidence instead of reopening the same issue.
Send the Issue to the Right Study Function
An issue enters the study log with a useful description but no clear function or urgency. The agent gathers related records and proposes only the operating route. Qualified staff confirm the handoff; any clinical, safety, protocol, quality, or regulatory concern leaves the standard queue immediately.
Bring the Evidence Into the Review Meeting
Quality and study owners should begin an internal review with complete evidence, not a request for screenshots. The agent assembles the specified events, correct artifact versions, reviewers, and unresolved exceptions. After validation, findings and follow-up leave the review meeting with that evidence still directly attached.
Build Your Own
Startup completeness, activation blockers, monitoring follow-up, TMF exceptions, issue routing, and evidence assembly create useful starting points when the expert handoff remains explicit.
Map Your First AI OpportunityThe agent must know exactly which study, site, artifact, version, and role it is serving before it prepares anything.
Trial-management records, site files, TMF artifacts, monitoring notes, and issue logs each carry part of the work. The system preserves study, site, country or region where applicable, artifact type, and version. An uncertain association stops for staff instead of crossing study boundaries.
The agent may prepare a checklist, follow-up, or route. CRAs, CTMs, investigators, medical and safety staff, quality, and regulatory teams keep their assigned responsibilities. Potentially clinical, safety-relevant, protocol, or regulatory content bypasses the ordinary queue for qualified review.
Baseline startup cycle, action age, document exceptions, corrections, and staff preparation time. Pilot across representative sites and messy artifacts—not only the clean package. Production monitoring follows wrong-study matches, missed escalation, overrides, reliability, and change history.
A structured comparison of CRO queues by study impact, staff effort, controlled-record readiness, exception burden, expert boundary, and functional ownership.
Opportunity Map · sample
value × readiness
★ Recommended first build
Controlled study records
study · site · artifacts
Functional access
role · study · purpose
Study procedures
requirements · gates · escalation
The agent
organizes · traces · escalates
Qualified review
study professionals decide
Controlled update
status · action · owner
Traceable history
sources · versions · approvals
The build works across the system categories carrying study, site, trial-document, issue, and quality work while preserving the controlled record.
Study and site operations
Clinical trial management systems
studies · sites · milestones · tasks
Site collaboration systems
requests · documents · communication
Trial records
Trial document repositories
artifacts · versions · completeness
Data and issue systems
queries · status · assigned actions
Quality and oversight
Quality systems
reviews · findings · follow-up
Study reporting
events · baselines · evidence
Metacto has 20+ years of software-delivery experience and more than 100 products shipped. Those company-wide facts are not CRO outcomes; each study-operations build must prove itself inside the organization's quality model.
20+
years building production software
100+
products shipped across industries
What makes this work
What stays with your team
Choose the work, structure the study file, ship under qualified review, and operate it through change.
Opportunity Mapping
You get The study queue worth funding, its baseline, expert boundary, and owner.
Context Engineering
You get Study and site identity, versions, permissions, procedures, and escalation rules.
Agents & Workflows
You get A live agent that prepares, requests qualified review, and updates controlled records.
Continuous AI Operations
You get Quality, escalation, reliability, cost, and controlled change managed over time.
An AI workflow in clinical research should start with high-volume coordination, controlled records, and a clear functional owner. Startup package readiness or TMF exception routing is easier to govern than work requiring clinical, safety, protocol, quality, or regulatory interpretation.
No. AI for clinical research should support coordination, not clinical or safety judgment. It can organize, check, draft, route, and track study work, while investigators, CRAs, CTMs, medical and safety personnel, quality, and regulatory teams retain their assigned decisions.
Access and retrieval are scoped by study, site, artifact, version, role, and task. An uncertain identity or match stops the work and routes it to staff before any prepared output enters a controlled record.
No. Traceability supports oversight. The CRO and sponsor determine applicable validation, quality, regulatory, privacy, and contractual requirements and approve the evidence and procedures for their environment.
Clinical operations automation should be measured through startup package cycle, blocker age, follow-up preparation, TMF exception age, corrections, and staff time. Add wrong-study matches, missed escalation, and overrides to the quality review.
Version the procedures, rules, sources, tests, and releases. Material protocol, process, or source-system changes trigger impact review and retesting under the organization's approved process.
Provider, insurance, and education teams share document and review pressure with CROs, while study-specific authority and records remain distinct.
Rank CRO queues by study value, record readiness, and expert risk.
Clinical Trial AI Opportunity Map
Tell us where startup, site coordination, monitoring follow-up, TMF exceptions, or evidence create the most drag. We will map the work, study records, expert boundary, and value case.
We'll be in touch within one business day to discuss next steps.
Explore Opportunity Mapping